Isarna Therapeutics shares positive results from Phase 2 BETTER trial

News
Article

Image credit: AdobeStock/iKatod

(Image credit: AdobeStock/iKatod)

Isarna Therapeutics shared final positive results from the Phase 2 BETTER trial, which evaluated the candidate ISTH0036 to address retinal fibrosis. ISTH0036 is an investigational antisense oligonucleotide designed to selectively suppress the production of transforming growth factor beta 2 (TGF-β2), a key cytokine involved in fibrosis and disease progression in retinal pathologies.1

This data was presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting on May 6, 2025 by Isarna’s Chief Medical Officer, Prof. Marion R. Munk.

The BETTER study evaluated ISTH0036 in both treatment-naïve and anti-VEGF–pretreated but inactive patients across sites in Austria and India. Patients received intravitreal injections of ISTH0036 every eight weeks (Q8W). These patients experienced stable or improved best-corrected visual acuity (BCVA), along with meaningful anatomical improvements in the retina. All patient groups showed a reduction in central retinal thickness (CRT).1

The company noted1 that eyes with nAMD and fibrosis-associated hyperreflective material (HRM) exhibited a significant decrease in HRM volume following ISTH0036 treatment, contrasting sharply with increases seen in fellow eyes receiving standard anti-VEGF therapy. In DME patients, ISTH0036 reduced intraretinal fluid volume in treatment-naïve and previously anti-VEGF–treated eyes. Intraocular pressure remained, and the treatment was well tolerated.

In addition to presenting this data at the ARVO 2025 meeting in Salt Lake City, Utah, Prof. Marion R. Munk, CMO of Isarna Therapeutics is also quoted in the company’s press release1 on this news, saying, “The results from the BETTER trial underscore the potential of ISTH0036 as a first-in-class antifibrotic agent that directly targets TGF–β2–driven fibrosis—a key driver of disease progression in nAMD and DME. This is a promising advance toward transforming care for patients facing progressive vision loss despite optimal standard therapy. Isarna’s next step will be to discuss the results and our development strategy with regulators in the US and EU to move ISTH0036 into Phase 2b/ Phase 3 pivotal clinical studies.”

Reference:

1. Isarna Therapeutics Presents Positive Phase 2 BETTER Trial Final Results at ARVO 2025. Isarna Therapeutics. May 7, 2025. Accessed May 7, 2025. https://www.streetinsider.com/Globe+Newswire/Isarna+Therapeutics+Presents+Positive+Phase+2+BETTER+Trial+Final+Results+at+ARVO+2025/24752465.html

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.